What we read
The Phase 2 retatrutide publication (Jastreboff et al., NEJM 2023); the TRIUMPH-1, TRIUMPH-2, TRIUMPH-3, and TRIUMPH-4 Phase 3 readouts published through April 2026; Eli Lilly's quarterly investor presentations referencing the program; and the ClinicalTrials.gov entries for the TRIUMPH program (NCT05882045, NCT05952713, NCT05882187, NCT05996731). This is a literature synthesis, not a clinical-practice document.
The mechanism that produces the side-effect profile
Retatrutide is a triple receptor agonist — it activates the GLP-1, GIP, and glucagon receptors. The first two receptors are familiar from semaglutide (GLP-1 only) and tirzepatide (GLP-1 + GIP). The third receptor — glucagon — is what distinguishes retatrutide both clinically and in its side-effect profile.
Glucagon-receptor activation increases energy expenditure (the body burns more), which is part of why the published weight-loss curve continues sloping past the 48-week mark in retatrutide trials when GLP-1-only and GLP-1+GIP curves have begun to plateau. The same mechanism produces a modest cardiovascular signal that distinguishes retatrutide's safety profile from the predecessor compounds.
Side effects reported in published Phase 3 data
Across the TRIUMPH readouts available through April 2026, the side-effect profile clusters into four categories. Each is reported at frequencies broadly comparable to tirzepatide SURMOUNT figures except where noted.
1. Gastrointestinal events
GI side effects are the most-reported category across all GLP-1-class compounds, and retatrutide is no exception. Published Phase 3 frequencies:
- Nausea: most common; reported in roughly half of high-dose participants, predominantly during dose titration
- Vomiting: reported less frequently than nausea; rates broadly comparable to tirzepatide at equivalent dose-titration stages
- Diarrhea: reported in a meaningful minority of participants; generally dose-dependent
- Constipation: reported alongside diarrhea in different participant subsets; the mechanism is gastric-emptying modulation, which can produce either depending on baseline patterns
GI events are typically transient and concentrated in the dose-escalation phase. Tolerability improves at maintenance doses. The trial protocols use slower-than-typical titration schedules specifically to manage this.
2. Heart-rate elevation (the distinct signal)
This is the side-effect category that distinguishes retatrutide from tirzepatide and semaglutide. The published Phase 3 readouts show a 1–3 bpm mean increase in resting heart rate across the reported populations, dose-dependent, attributable to the glucagon-receptor activity.
The magnitude is modest. The clinical question — whether this signal translates into adverse cardiovascular outcomes at scale — is what TRIUMPH-5 is specifically designed to answer. As of April 2026, the TRIUMPH-5 efficacy readout against placebo for major adverse cardiovascular events is not yet published. Interim safety readouts have been acceptable; the headline outcome data is forthcoming.
This dimension is what differentiates retatrutide's safety profile from the GLP-1-only and GLP-1+GIP class members. Buyers reading the literature should hold this as the most important pending question.
3. Injection-site reactions
Reported at frequencies broadly comparable to tirzepatide and semaglutide injection-site rates. Most are mild — transient erythema, minor induration, occasional pruritus at the injection site. Discontinuation due to injection-site reactions is uncommon in the published data.
4. Discontinuation due to adverse events
The TRIUMPH Phase 3 readouts report discontinuation rates due to adverse events broadly comparable to tirzepatide SURMOUNT figures. This is meaningful given that retatrutide produces a larger weight-loss effect — the trade-off in tolerability is not, by the published data, proportional to the additional efficacy.
Side-effect dimensions not yet fully characterized
Three categories the published TRIUMPH program does not yet fully address:
Long-term durability beyond 88 weeks. The longest published extension data covers 88 weeks. Whether the side-effect profile remains stable beyond that window — particularly the heart-rate signal — is a published-data gap that ongoing extension studies will fill in over 2026–2028.
Cardiovascular outcomes at scale. TRIUMPH-5 is the trial designed to answer this. The interim safety readouts are acceptable; the efficacy readout against placebo for major adverse cardiovascular events is the bar GLP-1-class drugs face for any cardio-protective labeling. This data is not yet public.
Special populations. Pediatric, hepatic-impairment, and pregnant populations are not covered by the published TRIUMPH program. These are typical post-approval study commitments rather than Phase 3 program exclusions, but the side-effect profile in these populations is not yet characterized.
How retatrutide's profile compares to tirzepatide and semaglutide
A clean side-by-side on the dimensions that drive tolerability decisions:
| Dimension | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Mechanism | GLP-1 mono-agonist | GLP-1 + GIP dual-agonist | GLP-1 + GIP + glucagon triple-agonist |
| Peak Phase 3 weight loss (top dose, 48wk) | ~15% | ~21% | ~24% |
| GI side-effect profile | Class-typical | Class-typical | Class-typical |
| Heart-rate signal | Not characteristic | Not characteristic | 1–3 bpm elevation (glucagon) |
| Discontinuation-due-to-AE rate | Class-typical | Class-typical | Comparable to tirzepatide |
| FDA approval | Yes (Wegovy 2021) | Yes (Zepbound 2023) | No — Phase 3, FDA submission targeted 2026 |
The heart-rate signal is the single most important comparative distinction. Everything else in the published profile clusters near the tirzepatide reference figures.
What this does not tell you
Research-peptide retatrutide is not the same data point. The Phase 3 trials test pharma-grade retatrutide produced under cGMP conditions and titrated under medical supervision. Research-peptide samples sold outside that framework are subject to manufacturing variance, identity-confirmation gaps, and dose-titration without clinical oversight. The Janoshik 7,164-tests purity analysis documents the cross-vendor variance specifically for retatrutide: of the 200 publicly-submitted tests in our local mirror, retatrutide is the most-tested compound (44 tests) and historically had higher purity variance than tirzepatide.
The side-effect profile in the trials does not extrapolate to research-peptide use. Compound identity is the first variable; dose titration without clinical oversight is the second.
Sources
- Jastreboff et al., NEJM 2023 — Phase 2 retatrutide
- TRIUMPH program: ClinicalTrials.gov NCT05882045 (TRIUMPH-1), NCT05952713 (TRIUMPH-2), NCT05882187 (TRIUMPH-3), NCT05996731 (TRIUMPH-4)
- SURMOUNT-1 — tirzepatide Phase 3 comparator
- Eli Lilly investor relations — quarterly earnings calls 2025–2026, retatrutide program updates
- Internal: Retatrutide vs Tirzepatide research comparison, TRIUMPH-4 Phase 3 results read, Janoshik 7,164-tests purity analysis
Frequently asked
What are the most common side effects of retatrutide?
Across the TRIUMPH Phase 3 readouts, gastrointestinal events dominate: nausea (most common, reported in roughly half of high-dose participants during titration), vomiting, diarrhea, and constipation. Class-typical for GLP-1 compounds. The one distinct retatrutide signal is a 1–3 bpm mean heart-rate elevation attributable to the glucagon-receptor component (Jastreboff et al., NEJM 2023; TRIUMPH-1 through TRIUMPH-4).
How long do the GI side effects last?
Published Phase 3 data shows GI events concentrate during dose-escalation phases (initiation through the 4 mg / 8 mg titration steps), then taper at maintenance doses. The TRIUMPH protocols use a slower-than-typical titration (~4-week dwell at each step) specifically because tolerability scales with rate-of-change, not absolute dose. Most participants who tolerate titration tolerate maintenance.
Does retatrutide cause heart-rate increase?
Yes — the published Phase 3 readouts report a 1–3 bpm mean increase in resting heart rate, dose-dependent, attributable to glucagon-receptor activation. This is the side-effect category that distinguishes retatrutide from tirzepatide and semaglutide. Tirzepatide and semaglutide do not characteristically produce this signal.
How serious is the heart-rate signal in TRIUMPH?
The magnitude is modest (1–3 bpm mean). Whether it translates to adverse cardiovascular outcomes at scale is the question TRIUMPH-5 is designed to answer; the major adverse cardiovascular events readout against placebo is not yet published as of April 2026. Interim safety readouts have been acceptable. This is the most important pending data point in the program.
Can retatrutide cause sexual side effects?
Sexual side effects are not a prominent category in the published TRIUMPH Phase 3 readouts. Reddit discussions (e.g. "Help! Post Reta Stomach/Sex," 83 comments) raise libido and erectile concerns as user-reported observations, but these are anecdotal and not characterized in the peer-reviewed trial data. Confounders — rapid weight loss, GI symptoms, lifestyle changes — make causal attribution difficult outside controlled studies.
How does the retatrutide side-effect profile compare to tirzepatide?
GI events and discontinuation-due-to-AE rates are broadly comparable. The headline differences: retatrutide produces ~24% mean weight loss versus tirzepatide's ~21% at top tested doses, with discontinuation rates similar — so the tolerability trade-off is not proportional to the additional efficacy. The unique retatrutide signal is the 1–3 bpm heart-rate elevation, which is not characteristic of tirzepatide.